Table 1 Correlation between FFAR4 expression and clinicopathological characteristics in LUAD.

n

267

268

T stage, n (%)

 T1

77 (14.5%)

98 (18.4%)

 T2

151 (28.4%)

138 (25.9%)

 T3

25 (4.7%)

24 (4.5%)

 T4

13 (2.4%)

6 (1.1%)

N stage, n (%)

 N0

168 (32.4%)

180 (34.7%)

 N1

48 (9.2%)

47 (9.1%)

 N2

45 (8.7%)

29 (5.6%)

 N3

0 (0%)

2 (0.4%)

M stage, n (%)

 M0

188 (48.7%)

173 (44.8%)

 M1

16 (4.1%)

9 (2.3%)

Pathologic stage, n (%)

 Stage I

140 (26.6%)

154 (29.2%)

 Stage II

55 (10.4%)

68 (12.9%)

 Stage III

50 (9.5%)

34 (6.5%)

 Stage IV

16 (3%)

10 (1.9%)

Primary therapy outcome, n (%)

 PD

43 (9.6%)

28 (6.3%)

 SD

22 (4.9%)

15 (3.4%)

 PR

2 (0.4%)

4 (0.9%)

 CR

151 (33.9%)

181 (40.6%)

Gender, n (%)

 Female

129 (24.1%)

157 (29.3%)

 Male

138 (25.8%)

111 (20.7%)

Race, n (%)

 Asian

4 (0.9%)

3 (0.6%)

 Black or African American

32 (6.8%)

23 (4.9%)

 White

201 (42.9%)

205 (43.8%)

Age, n (%)

 ≤ 65

131 (25.4%)

124 (24%)

 >65

127 (24.6%)

134 (26%)

Residual tumor, n (%)

 R0

181 (48.7%)

174 (46.8%)

 R1

7 (1.9%)

6 (1.6%)

 R2

1 (0.3%)

3 (0.8%)

Anatomic neoplasm subdivision, n (%)

 Left

95 (18.3%)

110 (21.2%)

 Right

162 (31.2%)

153 (29.4%)

Anatomic neoplasm subdivision2, n (%)

 Central lung

33 (17.5%)

29 (15.3%)

 Peripheral lung

64 (33.9%)

63 (33.3%)

Number_pack_years_smoked, n (%)

 <40

89 (24.1%)

99 (26.8%)

 ≥ 40

104 (28.2%)

77 (20.9%)

Smoker, n (%)

 No

22 (4.2%)

53 (10.2%)

 Yes

238 (45.7%)

208 (39.9%)

Age, median (IQR)

65 (59.25, 72)

67 (59, 73)